Maze Therapeutics Stock
HealthTechLooking to sell Maze Therapeutics stock or options?
Maze Therapeutics has designed a biotechnology platform that is centered on transforming genetic insights into innovative medicines. The platform integrates comprehensive human genetic data analysis, functional genomics, and a range of drug discovery techniques to identify modifier genes that offer protection. This facilitates a more profound understanding of target biology and how these targets can be effectively addressed with drug treatments. This enables pharmaceutical companies to create novel therapeutic options.
Driehaus Capital Management, Moore Strategic Ventures, Janus Henderson Investors, Timefolio Capital, General Catalyst, Frazier Lifesciences Acquisition, Matrix Capital Management, Piper Sandler, Frazier Healthcare Partners, Alexandria Venture Investments, Logos Capital, Andreessen Horowitz, ARCH Venture Partners, Deep Track Capital, Third Rock Ventures, Casdin Capital, City Hill Ventures, Sanofi, GV, The Sobrato Organization, Terra Magnum Capital Partners, Moore Capital Management, Woodline Partners, Paratus Investment, Foresite Capital.